Physician

Young Thi Mcmahan, M.D.

According to 2025 Medicare claims, Young Mcmahan, M.D. (NPI: 1013352145) practices dermatology in the Waco, TX market, with the plurality of this provider's patient population coming from Mc Lennan, TX. This provider's primary affiliated billing organization is OLIVER STREET 5.01(A) INC. (NPI: 1457695413; TIN: 461314303) and primary practice location at 76712-7935.

Mcmahan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 893 traditional Medicare patients, billed 6,248 HCPCS/CPT codes, and received $317,409 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,288 prescription claims across 465 beneficiaries totaling $758,054 in drug costs, led by Skyrizi Pen (Risankizumab-Rzaa). Open Payments data shows 124 records totaling $2,341. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $68,767 to $317,409. Similarly, Part D prescription costs have moved sharply higher in recent years, from $41,183 to $758,054. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$162K$323K2017 Medicare payment: $68,767 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $213,259 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $323,468 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $205,809 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $225,479 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $277,520 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $292,730 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $317,409 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
20173601,597$68,767
20187135,288$213,259
20191,1027,470$323,468
20209205,366$205,809
20218475,170$225,479
20229176,556$277,520
20239276,390$292,730
20248936,248$317,409

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$379K$758K2015 Drug cost: $41,183 (USD; Tot_Drug_Cst)2016 Drug cost: $33,749 (USD; Tot_Drug_Cst)2017 Drug cost: $55,856 (USD; Tot_Drug_Cst)2018 Drug cost: $87,478 (USD; Tot_Drug_Cst)2019 Drug cost: $103,794 (USD; Tot_Drug_Cst)2020 Drug cost: $204,664 (USD; Tot_Drug_Cst)2021 Drug cost: $119,289 (USD; Tot_Drug_Cst)2022 Drug cost: $404,049 (USD; Tot_Drug_Cst)2023 Drug cost: $612,794 (USD; Tot_Drug_Cst)2024 Drug cost: $758,054 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015140321$41,183
201692224$33,749
2017197396$55,856
2018335892$87,478
2019389925$103,794
2020348839$204,664
2021374911$119,289
2022343856$404,049
20234281,044$612,794
20244651,288$758,054

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more246359$90
11102Biopsy of related skin growth, first growth259312$72
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more611981$62
17000Destruction of precancer skin growth, 1 growth440676$40
17003Destruction of precancer skin growth, 2-14 growths3552,431$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Skyrizi PenRisankizumab-Rzaa131,092$262,009
Dupixent PenDupilumab611,792$229,840
Humira(Cf) PenAdalimumab13364$86,913
Clobetasol PropionateClobetasol Propionate1574,695$6,807
KetoconazoleKetoconazole1744,983$3,194

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.124$2,341ABBVIE INC.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Young Thi Mcmahan, M.D.?

Tedicare shows public-source Medicare data for Young Thi Mcmahan, M.D. (NPI 1013352145), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Young Thi Mcmahan, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Young Thi Mcmahan, M.D.?

Young Thi Mcmahan, M.D. is linked to OLIVER STREET 5.01(A) INC. (billing NPI 1457695413) in the available physician profile data.

Does Young Thi Mcmahan, M.D. have Open Payments data?

Young Thi Mcmahan, M.D. has 124 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.